📗 Cite This Artifact
Linked Clinical Trials (Cure Parkinson's)
Introduction
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Linked Clinical Trials (LCT) Program
|-
| Established | 2009
|-
| Lead Organization | [Cure Parkinson's](/institutions/cure-parkinsons)
|-
| Type | International Clinical Trials Consortium
|-
| Focus | Accelerating disease-modifying therapies for [Parkinson's disease](/diseases/parkinsons-disease)
|-
| Website | [linkedclinicaltrials.org](https://www.linkedclinicaltrials.org)
|}
</div>
Overview
Linked Clinical Trials (LCT) is the flagship international clinical trials program of [Cure Parkinson's](/institutions/cure-parkinsons), a UK-based charity dedicated to finding a cure for [Parkinson's disease](/diseases/parkinsons-disease). Founded in 2009, LCT represents a unique approach to drug repurposing, bringing together leading [Parkinson's disease](/diseases/parkinsons-disease) researchers, pharmaceutical companies, and people with [Parkinson's disease](/diseases/parkinsons-disease) to rapidly advance promising disease-modifying therapies through clinical trials.
The program has reviewed over 200 compounds and has been instrumental in advancing more than 30 repurposed drugs into clinical trials for [Parkinson's disease](/diseases/parkinsons-disease), making it one of the most productive drug repurposing initiatives in the [Parkinson's disease](/diseases/parkinsons-disease) field.
Program Structure
International Committee
...
Introduction
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Linked Clinical Trials (LCT) Program
|-
| Established | 2009
|-
| Lead Organization | [Cure Parkinson's](/institutions/cure-parkinsons)
|-
| Type | International Clinical Trials Consortium
|-
| Focus | Accelerating disease-modifying therapies for [Parkinson's disease](/diseases/parkinsons-disease)
|-
| Website | [linkedclinicaltrials.org](https://www.linkedclinicaltrials.org)
|}
</div>
Overview
Linked Clinical Trials (LCT) is the flagship international clinical trials program of [Cure Parkinson's](/institutions/cure-parkinsons), a UK-based charity dedicated to finding a cure for [Parkinson's disease](/diseases/parkinsons-disease). Founded in 2009, LCT represents a unique approach to drug repurposing, bringing together leading [Parkinson's disease](/diseases/parkinsons-disease) researchers, pharmaceutical companies, and people with [Parkinson's disease](/diseases/parkinsons-disease) to rapidly advance promising disease-modifying therapies through clinical trials.
The program has reviewed over 200 compounds and has been instrumental in advancing more than 30 repurposed drugs into clinical trials for [Parkinson's disease](/diseases/parkinsons-disease), making it one of the most productive drug repurposing initiatives in the [Parkinson's disease](/diseases/parkinsons-disease) field.
Program Structure
International Committee
The LCT is governed by an international committee of leading [Parkinson's disease](/diseases/parkinsons-disease) researchers who evaluate compounds based on:
| Evaluation Criterion | Weight |
|---------------------|--------|
| Scientific Rationale | High |
| Preclinical Evidence | High |
| Safety Profile | High |
| Feasibility | Medium |
| Patient Accessibility | Medium |
Committee Members (Past and Present)
- Prof. Roger Barker (Cambridge, UK) - Committee Chair
- Prof. Ray Chaudhuri (London, UK)
- Prof. K. Ray Chaudhuri - King's College London
- Prof. David Dexter ([Parkinson's UK](/institutions/parkinsons-uk))
- Prof. Michel Grothe (Spain)
- Prof. Per Odin (Germany)
- Prof. Tomasz Wojcieszek (Poland)
- Prof. Paolo Calabresi (Italy)
Industry Partners
The program collaborates with pharmaceutical companies to access compounds and fund clinical trials:
- Pharmaceutical companies with relevant compounds in their portfolio
- Biotechnology companies developing novel therapies
- Generic drug manufacturers for off-patent compounds
Drug Pipeline
Phase I: Compound Review
The committee meets annually to review new compounds based on:
Selection Criteria
- [Alpha-synuclein](/proteins/alpha-synuclein) aggregation
- [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Lysosomal dysfunction](/mechanisms/lysosomal-dysfunction)
- [Neurotrophic factor](/proteins/gdnf) signaling
- Neuroprotection in toxin models (MPTP, 6-OHDA)
- Alpha-synuclein propagation models
- Genetic PD models ([LRRK2](/genes/lrrk2), [GBA](/genes/gba), [SNCA](/genes/snca))
- Approved for other indications
- Established dosing regimens
- Documented side effect profile
Phase II: Trial Design
Selected compounds advance to clinical trial planning:
| Stage | Description |
|-------|-------------|
| Protocol Development | Customized trial design for [Parkinson's disease](/diseases/parkinsons-disease) |
| Regulatory Submission | CTA/IND applications |
| Site Selection | International trial centers |
| Patient Recruitment | Partnership with patient organizations |
Phase III: Clinical Execution
Multi-site, international clinical trials:
- Phase IIa: Proof-of-concept (typically 6-12 months)
- Phase IIb: Dose-finding/efficacy (typically 12-24 months)
- Phase III: Confirmatory trials
Pipeline Drugs
Currently in Clinical Trials
| Drug | Original Indication | PD Target | Trial Phase |
|------|---------------------|-----------|--------------|
| [Exenatide](/therapeutics/exenatide-parkinsons-disease) | Diabetes | [GLP-1R](/proteins/glp-1-receptor) | Phase III |
| [Ambroxol](/therapeutics/ambroxol-parkinsons) | Mucolytic | [GBA](/genes/gba) | Phase II |
| Inosine | Gout | Urate elevation | Phase III |
| [Nilotinib](/therapeutics/nilotinib-parkinsons) | Leukemia | [Autophagy](/mechanisms/autophagy) | Phase II |
| Simvastatin | High cholesterol | Neuroprotection | Phase II |
| Metformin | Diabetes | AMPK | Phase II |
Recently Completed Trials
| Drug | Trial Phase | Outcome |
|------|-------------|---------|
| Exenatide | Phase II | Positive motor outcomes |
| Ambroxol | Phase II | Safe, GBA activity increased |
| Inosine | Phase II | Urate raised safely |
| Rasagiline | Phase III | Mixed results |
Pipeline Overview
Key Achievements
Clinical Trial Milestones
- First positive Phase II trial of a [GLP-1](/proteins/glp-1-receptor) agonist in [Parkinson's disease](/diseases/parkinsons-disease)
- Showed significant improvement in motor scores
- Paved way for Phase III trial
- First targeted therapy for [GBA](/genes/gba)-associated [Parkinson's disease](/diseases/parkinsons-disease)
- Demonstrated increased GBA enzyme activity
- Ongoing Phase II/III trial
- Largest urate elevation trial in [Parkinson's disease](/diseases/parkinsons-disease)
- Demonstrated safety and target engagement
- Phase III ongoing
- First use of tyrosine kinase inhibitor in [Parkinson's disease](/diseases/parkinsons-disease)
- Showed [autophagy](/mechanisms/autophagy) pathway activation
- Phase IIb trial planned
Impact Metrics
| Metric | Value |
|--------|-------|
| Compounds Reviewed | 200+ |
| Trials Initiated | 30+ |
| Countries Involved | 15+ |
| Patients Enrolled | 5,000+ |
| Funding Raised | £50M+ |
Collaboration Model
Academic Partnerships
- University research centers worldwide
- Hospital-based [Parkinson's disease](/diseases/parkinsons-disease) research programs
- Independent research organizations
Pharmaceutical Partnerships
- Compound donation programs
- Co-funding arrangements
- Data sharing agreements
Patient Involvement
- People with [Parkinson's disease](/diseases/parkinsons-disease) involved in trial design
- Patient advocacy representation on committee
- Recruitment support through patient networks
Funding
The LCT program is funded through:
- [Cure Parkinson's](/institutions/cure-parkinsons) charitable donations
- Pharmaceutical company partnerships
- Research grants from foundations
- Individual donors
Drug Pipeline in Detail
Exenatide for Parkinson's Disease
Exenatide represents the most advanced therapeutic candidate in the LCT pipeline[@ayers2020]. Originally developed for type 2 diabetes, exenatide is a GLP-1 receptor agonist that has shown neuroprotective properties in preclinical models of Parkinson's disease.
Mechanism of Action:
GLP-1 receptors are expressed in the brain, including in dopaminergic neurons. Activation of these receptors promotes neuronal survival, reduces neuroinflammation, and enhances mitochondrial function. In Parkinson's disease models, exenatide treatment protects dopaminergic neurons from toxin-induced degeneration and improves motor function.
Clinical Development:
The Phase II trial demonstrated that exenatide treatment resulted in significant improvements in motor scores compared to placebo[@exenatide]. These results represented the first positive Phase II trial of a GLP-1 agonist in Parkinson's disease and paved the way for the ongoing Phase III trial. The Phase III trial is evaluating whether exenatide can slow disease progression in patients with early-to-mid stage Parkinson's disease.
Current Status:
The Phase III trial is enrolling patients across multiple international sites. Primary endpoints include change in motor scores and safety assessments. Secondary endpoints include biomarker measurements and non-motor symptom assessments.
Ambroxol for GBA-PD
Ambroxol represents a targeted therapy approach for Parkinson's disease patients with GBA mutations[@mulhall2020]. GBA mutations are among the most common genetic risk factors for Parkinson's disease, and impair the function of glucocerebrosidase, a lysosomal enzyme.
Mechanism of Action:
Ambroxol acts as a pharmacological chaperone that increases GBA enzyme activity. By restoring GBA function, ambroxol reduces accumulation of glucosylceramide, which may contribute to alpha-synuclein aggregation. This represents a disease-modifying approach targeting the underlying genetic cause in GBA-PD patients.
Clinical Development:
Phase II trials demonstrated that ambroxol safely increased GBA enzyme activity in cerebrospinal fluid[@ambroxol]. The treatment was well-tolerated with no significant adverse events. These results support advancement to Phase II/III trials that will evaluate whether ambroxol can slow disease progression in GBA-PD patients.
Current Status:
Phase II/III trials are evaluating ambroxol in patients with Parkinson's disease who carry GBA mutations. These trials include biomarker assessments to confirm target engagement and clinical endpoints to evaluate efficacy.
Inosine for Urate Elevation
Elevated serum urate has been associated with reduced Parkinson's disease risk in epidemiological studies. The LCT program has advanced inosine as a strategy to raise urate levels in Parkinson's disease patients[@scherer2020].
Mechanism of Action:
Urate is a natural antioxidant that may protect dopaminergic neurons from oxidative damage. Higher urate levels correlate with slower disease progression in Parkinson's disease. Inosine supplementation raises serum urate levels, potentially providing neuroprotection.
Clinical Development:
The SPRING trial demonstrated that inosine safely raises serum urate levels in Parkinson's disease patients. Target engagement was confirmed through measurement of urate in cerebrospinal fluid. The Phase III trial is evaluating whether urate elevation can slow disease progression.
Current Status:
Phase III trials are ongoing to evaluate the disease-modifying potential of inosine in Parkinson's disease. Patients are being monitored for both efficacy and safety endpoints.
Nilotinib for Parkinson's Disease
Nilotinib, originally developed for chronic myeloid leukemia, has been repurposed for Parkinson's disease based on its ability to activate autophagy[@paolone2019].
Mechanism of Action:
Nilotinib inhibits ABL tyrosine kinase, which activates the autophagy pathway. Enhanced autophagy may help clear toxic protein aggregates, including alpha-synuclein. This represents a novel approach to promoting protein clearance in Parkinson's disease.
Clinical Development:
Phase II trials demonstrated that nilotinib is safe in Parkinson's disease patients and shows evidence of autophagy pathway activation. The drug penetrates the blood-brain barrier at concentrations that inhibit ABL. Phase IIb trials are planned to evaluate efficacy.
Current Status:
Phase IIb trials are being designed to evaluate whether nilotinib can provide disease-modifying benefits in Parkinson's disease.
Additional Pipeline Drugs
Simvastatin:
Simvastatin, a cholesterol-lowering drug, has neuroprotective properties that may benefit Parkinson's disease patients[@chaturvedi2021]. The LCT has advanced simvastatin to Phase II trials evaluating its disease-modifying potential.
Metformin:
Metformin activates AMPK, a cellular energy sensor that promotes metabolic health and may provide neuroprotection[@meissner2021]. Phase II trials are evaluating metformin in Parkinson's disease.
Additional Pipeline Candidates
The LCT continuously evaluates new compounds for the drug repurposing pipeline. Several candidates are in various stages of preclinical and early clinical development:
Neurotrophic Factors:
GDNF and related neurotrophic factors have shown promise in preclinical models of Parkinson's disease. These proteins promote the survival and function of dopaminergic neurons. The LCT has supported early-stage clinical work on neurotrophic factor delivery approaches.
Antioxidants:
Given the role of oxidative stress in Parkinson's disease pathogenesis, antioxidants represent another therapeutic strategy. Coenzyme Q10 and other compounds have been evaluated in clinical trials supported by the LCT program.
Anti-inflammatory Agents:
Chronic neuroinflammation contributes to Parkinson's disease progression. The LCT has evaluated anti-inflammatory agents that may modulate microglial activation and reduce neuroinflammation.
Combination Therapy Approaches
Future directions include combination therapy approaches that target multiple pathological pathways simultaneously:
- GLP-1 agonists with alpha-synuclein aggregation inhibitors
- GBA chaperones with autophagy enhancers
- Urate elevation with neuroprotective agents
These combination approaches may provide greater disease-modifying benefits than single-agent therapies.
Impact on Parkinson's Disease Field
Accelerating Drug Development
The LCT program has significantly accelerated the drug repurposing pipeline for Parkinson's disease. By providing a systematic approach to evaluating existing drugs, the program has moved more than 30 compounds into clinical trials that would not otherwise have been tested in Parkinson's disease.
Building Research Infrastructure
The program has established infrastructure that benefits the entire Parkinson's disease research community:
- Standardized clinical trial protocols
- International collaboration networks
- Patient engagement frameworks
- Biomarker development programs
Influencing Research Priorities
The LCT has influenced research priorities in the Parkinson's disease field by highlighting the importance of drug repurposing and disease modification. This has led to increased funding and interest in these areas.
Scientific Leadership
Publications and Citations
LCT research has been highly influential, with numerous publications in high-impact journals. The program's work on Exenatide, Ambroxol, and other candidates has been cited extensively in the scientific literature.
Conference Presentations
LCT investigators regularly present their findings at major conferences including:
- Movement Disorders Society meetings
- American Academy of Neurology annual meeting
- Parkinson's Disease conferences
- World Parkinson Congress
Training and Education
The LCT supports training the next generation of Parkinson's disease researchers through:
- Clinical fellowship programs
- Research training opportunities
- Patient education initiatives
- Healthcare professional education
Program Sustainability
Funding Model
The LCT maintains sustainability through diverse funding sources:
Charitable Funding:
Cure Parkinson's provides core funding that supports program operations. Individual donors and charitable foundations contribute to the program's activities.
Industry Partnerships:
Pharmaceutical company partnerships provide both funding and in-kind support for clinical trials. These partnerships are structured to ensure scientific independence.
Research Grants:
Competitive research grants from government and charitable sources support specific research projects and clinical trials.
Strategic Planning
The LCT develops strategic plans that guide program priorities:
- Annual review of the drug pipeline
- Identification of emerging therapeutic targets
- Assessment of research infrastructure needs
- Evaluation of international collaboration opportunities
Conclusion
The Linked Clinical Trials program represents a unique and successful approach to accelerating disease-modifying therapies for Parkinson's disease. Through systematic evaluation of existing drugs, rigorous clinical trial design, and strong international collaboration, the program has advanced more than 30 compounds into clinical testing. The Exenatide Phase III trial and other ongoing studies represent the culmination of years of effort to bring disease-modifying therapies to Parkinson's disease patients. As the program continues to evaluate new candidates and advance the current pipeline, it remains a central pillar in the effort to find effective treatments for Parkinson's disease.
Committee Governance
Selection Process
The LCT international committee follows a rigorous process for evaluating potential therapeutic candidates:
Annual Review Meeting:
The committee meets annually to review new compounds and evaluate the progress of ongoing trials. This meeting brings together leading Parkinson's disease researchers, patient representatives, and industry partners.
Evaluation Criteria:
Compounds are evaluated based on scientific rationale, preclinical evidence, safety profile, feasibility, and patient accessibility[@bjorklund2022]. Only compounds with strong evidence supporting their potential benefit are advanced to clinical trials.
Committee Structure
The committee includes leading Parkinson's disease researchers from around the world:
- Prof. Roger Barker (University of Cambridge) - Committee Chair
- Prof. Ray Chaudhuri (King's College London) - International coordination
- Prof. David Dexter (Parkinson's UK) - Research strategy
- Prof. Michel Grothe (Spain) - Clinical trials
- Prof. Per Odin (Germany) - Drug development
- Prof. Tomasz Wojcieszek (Poland) - Patient engagement
- Prof. Paolo Calabresi (Italy) - Basic science translation
Clinical Trial Design
Endpoints and Outcomes
The LCT program has pioneered innovative clinical trial designs for Parkinson's disease[@vancamp2022]:
Motor Endpoints:
- Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores
- Timed motor tests
- Gait and balance assessments
- Cognitive assessments
- Sleep questionnaires
- Quality of life measures
- CSF biomarkers including alpha-synuclein and neurofilament light
- Blood biomarkers
- Neuroimaging markers[@park2021]
Trial Phases
Phase IIa:
Proof-of-concept trials typically enroll 50-100 patients and run for 6-12 months. These trials evaluate safety and preliminary efficacy signals.
Phase IIb:
Dose-finding and efficacy trials enroll 100-200 patients and run for 12-24 months. These trials establish optimal dosing and gather efficacy data to support Phase III trials.
Phase III:
Confirmatory trials enroll 300-500 patients and run for 24-36 months. These trials provide the definitive evidence needed for regulatory approval.
Patient Engagement
LCT Patient Advisory Board
The LCT program includes a Patient Advisory Board that provides input on trial design, recruitment strategies, and research priorities. This ensures that patient perspectives are incorporated into all aspects of the program.
Recruitment Partnerships
LCT works with patient organizations to support recruitment for clinical trials:
- Parkinson's UK
- Michael J. Fox Foundation
- National Parkinson's Foundation
- European Parkinson's Disease Association
Patient-Reported Outcomes
Patient-reported outcomes are incorporated into clinical trials to capture the full impact of treatments on quality of life[@deer2021].
Research Impact
Publications and Presentations
LCT research has been published in leading journals and presented at major conferences:
- [Movement Disorders](/diseases/movement-disorders)
- Lancet Neurology
- Neurology
- Parkinson's Disease journals
Collaborative Networks
LCT collaborates with international research networks:
- Parkinson's Progression Marker Initiative (PPMI)
- International Parkinson's Disease Genomics Consortium
- European Parkinson's Disease Association
Future Directions
Emerging Therapeutics
The LCT program continues to evaluate new therapeutic candidates:
- Gene therapy approaches
- Cell replacement therapies
- Novel neuroprotective agents
- Combination therapies targeting multiple pathways
Precision Medicine
LCT is developing approaches to target therapy based on patient genetics:
- GBA mutation carriers
- LRRK2 mutation carriers
- Other genetically defined subgroups
Biomarker Development
Continued biomarker development will enable:
- Patient selection for clinical trials
- Treatment response monitoring
- Disease progression tracking
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | institutions-linked-clinical-trials-cure-parkinsons |
| kg_node_id | None |
| entity_type | institution |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-0c026d627729 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-linked-clinical-trials-cure-parkinsons'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-institutions-linked-clinical-trials-cure-parkinsons?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Linked Clinical Trials (Cure Parkinson's)](http://scidex.ai/artifact/wiki-institutions-linked-clinical-trials-cure-parkinsons)
http://scidex.ai/artifact/wiki-institutions-linked-clinical-trials-cure-parkinsons